Qualigen Therapeutics Relocates Principal Executive Offices
Ticker: AIXC · Form: 8-K · Filed: Nov 1, 2024 · CIK: 1460702
Sentiment: neutral
Topics: corporate-action, filing
TL;DR
Qualigen moved offices effective Oct 25. New address: 5857 Owens Ave, Ste 300, Carlsbad, CA 92008. Phone: (760) 452-8111.
AI Summary
Qualigen Therapeutics, Inc. filed an 8-K on November 1, 2024, reporting a change in its principal executive offices to 5857 Owens Avenue, Suite 300, Carlsbad, California 92008, effective October 25, 2024. The company also reported amendments to its Articles of Incorporation or Bylaws and provided Regulation FD disclosures. The phone number for the new principal executive offices is (760) 452-8111.
Why It Matters
A change in principal executive offices can indicate operational shifts or restructuring within the company. Investors should monitor if this move is associated with cost savings, expansion, or other strategic initiatives.
Risk Assessment
Risk Level: low — This filing primarily concerns a change in the company's physical address, which is a routine administrative event with low direct financial risk.
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — Registrant
- October 25, 2024 (date) — Effective date of change in principal executive offices
- November 1, 2024 (date) — Filing date of the 8-K
- 5857 Owens Avenue, Suite 300, Carlsbad, California 92008 (location) — New principal executive offices address
- (760) 452-8111 (phone_number) — Phone number for new principal executive offices
FAQ
What is the new address for Qualigen Therapeutics, Inc.'s principal executive offices?
The new address for Qualigen Therapeutics, Inc.'s principal executive offices is 5857 Owens Avenue, Suite 300, Carlsbad, California 92008.
When was the change in principal executive offices effective?
The change in principal executive offices was effective October 25, 2024.
What is the phone number associated with the new principal executive offices?
The phone number associated with the new principal executive offices is (760) 452-8111.
What other items are reported in this 8-K filing?
This 8-K filing also reports amendments to Articles of Incorporation or Bylaws and Regulation FD disclosures.
What was the previous principal executive office address?
The filing does not explicitly state the previous principal executive office address, only the new one.
Filing Stats: 907 words · 4 min read · ~3 pages · Grade level 11 · Accepted 2024-11-01 16:55:34
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex3-1.htm (EX-3.1) — 1KB
- ex99-1.htm (EX-99.1) — 14KB
- ex3-1_001.jpg (GRAPHIC) — 1360KB
- ex99-1_001.jpg (GRAPHIC) — 20KB
- 0001493152-24-043352.txt ( ) — 2131KB
- qlgn-20241025.xsd (EX-101.SCH) — 3KB
- qlgn-20241025_lab.xml (EX-101.LAB) — 33KB
- qlgn-20241025_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: November 1, 2024 By: /s/ Kevin A. Richardson II Kevin Richardson II, Interim Chief Executive Officer